Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies[1][2][3].
Cagrilintide acetate (compound 23) (0.1, 1, 3, 10, 30 nmol/kg; s.c.single) reduces food intake in the rat[1].
Cagrilintide acetate (10 nmol/kg; i.v. or s.c.; single) shows good pharmacokinetic parameters[1].
| Animal Model: | Sprague Dawley male rats (12-week-old; ~400 g)[1] |
| Dosage: | 0.1, 1, 3, 10, 30 nmol/kg |
| Administration: | Subcutaneous injection; single |
| Result: | Reduced food intake in the rat for several days at doses in the range of 1-10 nmol/kg. |
| Animal Model: | Sprague Dawley male rats (12-week-old; ~400 g)[1] |
| Dosage: | 10 nmol/kg |
| Administration: | Intravenous injection or subcutaneous injection; single |
| Result: | Showed good pharmacokinetic parameters with T1/2 of 20, 27 h for i.v. and s.c., respectively. |
[1]. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 Aug 12;64(15):11183-11194.
[2]. Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021 Jun;377(3):417-440.
[3]. Dehestani B, et al. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021 Dec 30;30(4):320-325.